Bioqual (BIOQ) Akcija Kursas
Bioqual Kursas
Pajamos augo 4,1 % per metus per pastaruosius 22 metus iki 39,95 mln. USD. Pelnas akcijai mažėjo 1,7 % per metus per pastaruosius 20 metus. Bioqual grynoji marža dabar yra −10,4 %, sumažėjo nuo 8,0 % prieš kelerius metus. Bioqual šiuo metu siūlo apie 1,52 % dividendo pajamingumą. Išmokų koeficientas yra apie 54 % pelno. Dividendas augo 8,3 % per metus per pastaruosius 19 metus.
Bioqual akcijos kaina
Gaukite šiuos duomenis per Eulerpool API
100 000 užklausų/mėn. nemokamai · be kortelės
Bioqual akcija ir akcijų analizė
Dažnai užduodami klausimai apie Bioqual akciją
The business model of Bioqual Inc is to provide contract research services to biotechnology and pharmaceutical companies, government agencies, and academic institutions. Bioqual specializes in preclinical and clinical research, including animal model development, in vitro testing, and regulatory compliance. Through collaboration with clients, Bioqual aims to advance the development of drugs, vaccines, and therapeutics, ultimately contributing to the improvement of human and animal health. With its expertise and state-of-the-art facilities, Bioqual Inc has established itself as a trusted partner in the biomedical research industry.
Bioqual Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Bioqual Inc in the market include Company A, Company B, and Company C. These companies operate in the same industry and offer similar products and services to Bioqual Inc. Their competitive presence challenges Bioqual Inc's market position and drives innovation within the industry. Maintaining a competitive edge is crucial for Bioqual Inc to attract and retain customers, expand its market share, and achieve long-term success. As Bioqual Inc continues to navigate its way in the market, it recognizes the importance of monitoring and adapting to the strategies and offerings of its key competitors.
Bioqual Inc. is a reputable company with a rich history and background. Established in [year], Bioqual Inc. has been a leading player in the [industry] sector. The company specializes in [specific products/services] and has built a strong reputation for its commitment to innovation, quality, and customer satisfaction. With a team of experienced professionals and state-of-the-art facilities, Bioqual Inc. has consistently delivered outstanding results and garnered recognition for its contributions to [industry]. Over the years, Bioqual Inc. has expanded its presence globally and continues to be a trusted name in the [industry] market, providing sustainable solutions and driving advancements in [industry].
Bioqual Inc has achieved several significant milestones over the years. The company has successfully gained recognition as a leading biomedical research organization, specializing in preclinical and clinical testing services. Notably, Bioqual Inc has garnered a strong reputation for its contributions to drug development, infectious disease research, and vaccine testing. The company has also established numerous strategic partnerships with pharmaceutical and biotech companies, academia, and government agencies. Furthermore, Bioqual Inc has consistently demonstrated exceptional scientific expertise, state-of-the-art facilities, and a commitment to quality, making it a trusted name in the industry.
Bioqual Inc is primarily present in the United States.
Bioqual Inc represents a commitment to excellence in the field of biomedical research. With a strong emphasis on animal modeling and preclinical testing services, Bioqual is dedicated to paving the way for breakthrough discoveries in healthcare and life sciences. The company's corporate philosophy revolves around comprehensive expertise, innovative solutions, and ensuring the highest standards of animal welfare. By providing state-of-the-art facilities and a team of skilled professionals, Bioqual strives to support scientific advancements and contribute to the development of novel therapies and vaccines. With a focus on quality, reliability, and integrity, Bioqual Inc is trusted by leading pharmaceutical and biotechnology companies worldwide.
Pagal dabartinį kursą Bioqual akcija kainuoja 29,36 EUR (33,00 USD).
Bioqual Inc is a US-based company specializing in providing research services and products for the life sciences, pharmaceuticals, and biotechnology industries. The company was founded in 1981 and has been offering innovative solutions to its customers since then.
pelnas Bioqual yra 39,95 mln. USD. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
grynasis pelnas Bioqual yra −4,17 mln. USD. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) Bioqual šiuo metu yra −7,08. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti Bioqual akcijos vertę.
Kainų ir pardavimų santykis (KUV) Bioqual šiuo metu yra 0,74. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra Bioqual akcijos įvertinimo metrika.
Eulerpool kokybės balas Bioqual yra 1/10.
Bioqual ISIN yra US09065J1016. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
Bioqual prekybos žymė yra BIOQ. Ši biržos žymė naudojama Bioqual akcijoms prekiauti biržoje.
Bioqual akcija
Bioqual Pagrindiniai konkurentai
Bioqual FIGI
Visos Bioqual pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė Bioqual akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai Bioqual. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: